Kenvue Addresses Tylenol Safety Issues Amid Declining Stock Prices
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 05 2025
0mins
Source: MarketWatch
Kenvue Inc. Stock Decline: Shares of Kenvue Inc., the maker of Tylenol, experienced a significant drop, reaching a record low due to investor concerns over a forthcoming report linking acetaminophen use during pregnancy to autism.
Company's Response: Kenvue stated that numerous studies have shown no evidence that acetaminophen use during pregnancy is harmful, attempting to mitigate the impact of the negative speculation on their stock.
PFE
$25+Infinity%1D
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 29.08 USD with a low forecast of 24.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
10 Hold
1 Sell
Hold
Current: 25.090
Low
24.00
Averages
29.08
High
34.00
Current: 25.090
Low
24.00
Averages
29.08
High
34.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
